High-dose edoxaban safety favorability vs. warfarin greater in women than men

February 23, 2021

3 min read

Source/Disclosures

Published by:

Disclosures: Giugliano reports he received research support from Amgen, Anthos Therapeutics, Daiichi Sankyo; honoraria for CME lectures from Amgen, Daiichi Sankyo, Merck; and consultant fees from Amarin, American College of Cardiology, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers-Squibb, CryoLife, CVS Caremark, Daiichi Sankyo, Eli Lilly, Esperion, Gilead, GlaxoSmithKline, Janssen, Lexicon, Merck, Pfizer, SAJA Pharmaceuticals, Samsung and Servier. Please see the study for all other authors’ relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Among women with atrial fibrillation at elevated CV risk, treatment with high-dose edoxaban vs. warfarin conferred greater reduction in hemorrhagic stroke and major bleeding compared with men, with similar efficacy, researchers reported…

Want to know more click here go to source.

From Healio - February 24, 2021